Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women
The study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
-
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
The new goals support GSK's aim to create long-term value for shareholders and meet the needs of society.
-
GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases
If approved in the EU, Nucala would be the only treatment indicated for four eosinophil-driven diseases.
-
European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer
The European Commission has approved Zejula as first-line monotherapy maintenance treatment for adult patients with advanced ovarian cancer.
-
GSK delivers resilient performance, strong commercial execution and further strategic progress in Q3
GSK delivers resilient performance, strong commercial execution and further strategic progress in Q3
-
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
COVAX Facility is led by Gavi and aims to secure successful and equitable access to COVID-19 vaccines worldwide.
-
ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices
These findings build on recently presented healthcare provider and clinical staff survey perspectives.
-
ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability
Positive new findings from two studies of the investigational, long-acting regimen of cabotegravir and rilpivirine for treatment of HIV.
-
ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine
ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19
-
GSK presents positive clinical data on maternal and older adults RSV candidate vaccines
Phase I/II data presented at ID Week show the two FDA fast-tracked candidate vaccines trigger robust immune response and are well-tolerated
-
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
Long-acting regimen is based on co-administration of cabotegravir and rilpivirine injections once-monthly or once every 2-months
-
ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen
The TANGO 96-week data presented at HIV Glasgow 2020 also confirm Dovato’s well-established safety and tolerability profile
-
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
Initial Phase 3 results may be available as early as the end of 2020; complete results are anticipated in January 2021.
-
ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1
ViiV Healthcare present their three-year results from the phase III GEMINI 1 & 2 studies at the HIV Glasgow 2020 congress
-
ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress
Data presented will reinforce the potential to shift the treatment paradigm to 2-drug regimens (2DRs) for people living with HIV
-
ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices
ViiV Healthcare work with clinical staff at 18 diverse practice sites across different healthcare systems in France, Spain, Belgium, Germany
-
FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES)
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases
-
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Agreements relate to vaccine candidate using Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant.
-
GSK receives CHMP positive opinion recommending approval of Zejula (niraparib) as first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer
This opinion follows the expansion of Zejula’s indication in the US with approval by the US Food and Drug Administration earlier this year.
-
Sanofi and GSK confirm agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine
This confirmation follows the announcement on 31 July of advanced discussions between the companies and the EC.
